Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

XERS vs NUVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XERS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

XERS Overall Winner 6-Pillar Tally: XERS 5 – 1 NUVB Matrix Metrics: XERS 7 – 3 NUVB

As of Nov 20, 2026, Xeris Biopharma Holdings, Inc. (XERS) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XERS carries a Unified Composite Score of 35.7/100 (SELL) at $16.97 (63.6x Forward P/E, 12.7% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).

  • Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. XERS 35.7/100 SELL), XERS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.7% vs. -61.2% operating margin) and revenue trajectory (+44.2% vs. +242.6% YoY).
  • Technical & Structure Timing Caution: XERS trades in a Markup technical trend (SURGE options phase, RSI 81.7); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XERS vs NUVB
XERS NASDAQ Head-to-Head Winner
Xeris Biopharma Holdings, Inc. Common Stock
Pharmaceutical Preparations
$16.97
+2.11% 1D
Market Cap $3.0B
TTM Revenue $368M
Forward P/E 63.6x
Beta / 30D Vol -0.04β · 104% Vol
Unified Composite Score
35.7 / 100 SELL
Tech 50.0 Fund 34.0 Flow 71.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (23.8% over 20 days), RSI 82
RSI-14: 81.7 · SMA20: $13.88 · SMA50: $11.29
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87

6-Pillar Scorecard Institutional Category Breakdown (XERS 5 – 1 NUVB)

Columns: Metric · XERS · NUVB
1. Valuation Multiples XERS
Forward P/E 63.6x N/M
Trailing P/E 87.0x N/M
PEG Ratio N/M N/M
EV / Revenue 8.5x 7.4x
2. Growth & Scale NUVB
Revenue Growth (YoY) +44.2% +242.6%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) $368M $202M
Market Cap $3.0B $1.3B
3. Profitability & Quality XERS
Gross Margin 87.4% 85.8%
Operating Margin 12.7% -61.2%
Net Profit Margin -1.8% -67.4%
Return on Equity (ROE) -27.1% -49.1%
4. Balance Sheet & Cash Flow XERS
Cash Generation (TTM) $73M -$108M
Cash Flow Margin 19.7% -53.6%
Net Cash / Leverage $95M Net Debt (4.63x D/E) $146M Net Debt (1.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XERS
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 52.0% (12th %ile) 65.2% (26th %ile)
Put/Call OI Skew N/A 0.24x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat XERS
OpEx & R&D Intensity 74.7% of Rev ($275M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XERS (7) vs NUVB (3)
Institutional Metric XERS NUVB Criterion Row Edge
Market Capitalization
Scale
$3.0B $1.3B Larger Scale XERS
Trailing P/E Ratio
Valuation
87.0x N/M Lower Multiple XERS
Forward P/E Ratio
Valuation
63.6x N/M Lower Multiple XERS
Revenue Growth (YoY)
Growth
+44.2% +242.6% Higher Growth NUVB
Operating Margin (TTM)
Profitability
12.7% -61.2% Higher Margin XERS
Net Profit Margin
Profitability
-1.8% -67.4% Higher Margin XERS
Return on Equity (ROE)
Capital Efficiency
-27.1% -49.1% Higher ROE XERS
52-Week Range Position
Momentum
97% ($5–$17) 2% ($4–$10) Stronger Trend XERS
Beta / 30D Volatility
Risk Regime
-0.04β · 104% Vol 1.52β · 55% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
35.7 / 100 (SELL) 61.0 / 100 (BUY) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$368M $202M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.4% 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.5x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$73M ($95M Net Debt (4.63x D/E)) -$108M ($146M Net Debt (1.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XERS +75.41 pp
XERS: +56.26% · NUVB: -19.15%
3M Horizon XERS +137.95 pp
XERS: +94.16% · NUVB: -43.79%
6M Horizon XERS +193.64 pp
XERS: +174.15% · NUVB: -19.49%
1Y Horizon XERS +186.2 pp
XERS: +139.35% · NUVB: -46.85%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period XERS Revenue NUVB Revenue XERS Op. Margin NUVB Op. Margin Margin Leader
FY2020 $20M N/A -414.5% N/A XERS
FY2021 $50M N/A -232.2% N/A XERS
FY2022 $110M N/A -74.3% N/A XERS
FY2023 $160M N/A -26.8% N/A XERS
FY2024 $200M $10M -16.6% -7527.3% XERS
FY2025 $290M $60M 8.5% -338.7% XERS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XERS SURGE
5d in phase · OBV ACCUMULATION
Current IV 52.0%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact XERS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $16.60 · IV 60.5%

XERS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,660)

Compare $1,660 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 60.5% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $15 / $14 Bull Put Spread

Sell 3x $15P · Buy 3x $14P · 29d

Net Entry $138 Credit
Max Credit / Yield +$138 (+85.2% RoM)
Max Risk / Buffer -12.4% Cushion ($162 Mgn)
5d Edge & Liquidity 70% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $17 / $15 Bear Put Spread

Buy 2x $17P · Sell 2x $15P · 29d

Net Entry $74 Debit
T+5d @ -5% Drop +$43 (+59%)
Max Risk / Buffer $74 Capped
5d Edge & Liquidity 1.4x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XERS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.0B market capitalization and 12.7% operating margin.
OpEx & R&D Reinvestment 74.7% of Rev ($275M)
90D Engineering Disclosures 0 Published
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XERS vs NUVB Key Questions & Quantitative Answers

As of Nov 20, 2026, Xeris Biopharma Holdings, Inc. (XERS) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XERS carries a Unified Composite Score of 35.7/100 (SELL) at $16.97 (63.6x Forward P/E, 12.7% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. XERS 35.7/100 SELL), XERS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.7% vs. -61.2% operating margin) and revenue trajectory (+44.2% vs. +242.6% YoY). Technical & Structure Timing Caution: XERS trades in a Markup technical trend (SURGE options phase, RSI 81.7); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: XERS posts +44.2% YoY revenue growth and N/A YoY earnings growth on $368M TTM revenue (87.4% gross margin, 12.7% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), XERS cumulative revenue shifted +1350.0% while NUVB shifted +500.0%. In operating R&D and SG&A reinvestment, XERS deploys 74.7% of Rev ($275M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.

XERS screens cheaper on headline valuation multiples. XERS trades at 63.6x Forward P/E, 87.0x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (19.7% FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XERS (-27.1% ROE) versus NUVB (-49.1% ROE) capital efficiency.

In options market volatility and institutional positioning, XERS carries 52.0% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (-0.04β · 104% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.